CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...
Truist cuts Cargo Therapeutics rating, slashes PT to $7
Truist Securities revised its position on Cargo Therapeutics (NASDAQ:CRGX), currently trading at $13.19 with a market ...
Cargo Therapeutics stock tumbles after trial setback
Shares of CARGO Therapeutics , Inc. (NASDAQ:CRGX) plummeted 75% following the company's decision to discontinue its Phase 2 clinical trial for firicabtagene autoleucel, citing insufficient ...